Skip to content

Construction of a prospective cohort of multi-source biological samples from pneumonia patients and mining of multi-group biomarkers

Construction of a prospective cohort of multi-source biological samples from pneumonia patients and mining of multi-group biomarkers

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104729
Enrollment
Unknown
Registered
2025-06-23
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Interventions

Observation group:None

Sponsors

The Army Characteristic Medical Center of the People's Liberation Army of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age >=18 years old; 2) Meet the diagnostic criteria of "Guidelines for the diagnosis and treatment of community-acquired pneumonia (2023 edition)" of Chinese Respiratory Society. The diagnosis should be confirmed by at least one senior respiratory physician. 3) Bronchoscopy is clinically necessary (e.g., to confirm the diagnosis, rule out lung cancer, tuberculosis, or other diseases, or for topical treatment such as alveolar lavage); 4) The diagnosis of CAP should be made within one week for both outpatients and inpatients; 5) Patients or their legal representatives voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Previous history of lung transplantation; 3. There are contraindications to bronchoscopy, including but not limited to: 1) Severe cardiopulmonary dysfunction, unable to tolerate bronchoscopy; 2) coagulopathy with a risk of bleeding (meets either criteria) : a. Coagulation function shows a hypocoagulable state; b. platelet count = 0.4); b. Oxygenation index (PaO2/FiO2) <= 150 mmHg (or <= 20 kPa); 4) severe arrhythmia or unstable angina; 4. Patients with severe systemic diseases and expected survival time less than 3 months (such as advanced malignant tumors, end-stage organ failure, etc.); 5. Received chemotherapy, radiotherapy or immunosuppressive therapy within 2 weeks before admission (special cases need to be reviewed by the ethics committee); 6. If the sample size of BALF was not sufficient for metabolomics analysis (if the amount of BALF recovered during the operation was too small to meet the needs of subsequent detection, it was excluded);

Design outcomes

Primary

MeasureTime frame
Reduction rate of CT score;

Secondary

MeasureTime frame
Blod routine and infammatoryindicators (white blod cels, neutrophis, ymphocytes, ymphogyte subsets, platelets, -reactive protein, procalcitonin, serum amyloid protein,intereukin-6, TNF-a;PaO2/FiO2;

Countries

China

Contacts

Public ContactLi Li

The Army Characteristic Medical Center of the People's Liberation Army of China

lili10119@126.com+86 13983035673

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026